Efficacy of a program of prevention and control for methicillin-resistant Staphylococcus aureus infections in an intensive-care unit by Moreira, Marina et al.
www.bjid.com.br
BJID 2007; 11 (February) 5 7
Efficacy of a Program of Prevention and Control for
Methicillin-Resistant Staphylococcus aureus Infections in an Intensive-Care Unit
Marina Moreira1, Marise R. Freitas2, Sinaida T. Martins3, Adauto Castelo3 and Eduardo Alexandrino Servolo Medeiros3
1Taubaté University, Taubaté, SP; 2Federal University of Rio Grande do Norte, Natal, RN; 3Federal University of São Paulo, São Paulo, SP, Brazil
Methicillin-resistant Staphylococcus aureus (MRSA) is endemic in most Brazilian Hospitals, and there are few
studies which show the efficacy of control measures in such situations. This study evaluated intensive care unit
(ICU) patients, in two years divided in control, intervention and post-intervention group. Intervention measures:
hands-on educational programs for healthcare workers; early identification of MRSA infected or colonized patients,
labeled with a bed-identification tag for contact isolation; nasal carriers, patients, and healthcare professionals
treated with topical mupirocin for five days. The hospital infection rates in the control period were compared to the
ones in the post-intervention period. Hospital infection rates were found by means of the NNISS methodology The
incidence coefficients of MRSA hospital infection (monthly average of 1,000 pts/day) in the control, intervention
and post-intervention groups were respectively: 10.2, 5.1 and 2.5/1,000 pts/day (p<0.001) and MRSA-originated
bloodstream infections were 3.6, 0.9 and 1.8/1,000 central venous catheter/day (p=0.281). Nasal colonization in both
intervention and post-intervention periods was of 30.9% and 22.1% among the hospitalized patients, respectively
54.4% and 46.1% of whom were already MRSA-positive when admitted to the unit. In the intervention period, most
of those MRSA infected patients (76.2%) were nasal carrier. Mortality rates were, respectively 26.6%; 27.3% and
21.0% (p<0.001). Nasal carriers, both patients (93.7%) and healthcare professionals (88.2%), were successfully
treated with topical mupirocin. Intervention measures for the prevention and control of MRSA infections in ICUs,
have been efficient in the reduction of the bloodstream and MRSA-originated hospital infections incidence, and
reduced the overall mortality rate significantly.
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Methicillin-resistant Staphylococcus aureus (MRSA) is
currently deemed a ubiquitous pathogen, that gives rise to
community acquired infections, endemic and epidemic hospital
infection and colonization. Concern about infections arising
from such microorganism increases as changes in its
epidemiology occur, with an increased number of community
acquired cases¹ and the emergence of vancomycin-reduced
susceptibility strains [1,2]. High prevalence of MRSA in the
large Brazilian public and university hospitals has been found.
In our setting, 73.2% of bloodstream S. aureus hospital
infections arose from MRSA [3]. ICUs are important reservoirs
in the MRSA epidemiology, and they may be a source of
dissemination to other areas of the hospital [3-5].
Studies on MRSA control measures are controversial, on
account of the diversity of situations which require intervention
[6]. Some authors believe that no effort to control the
microorganism should be made unless upon outbreaks or to
prevent the emergence of antibiotics resistance [4,7,8].
Evaluated single measures or measures in different
combinations proved to be effective even at MRSA endemic
level institutions  [5,7,9].
There are evidence that MRSA nasal carriers contribute
towards the development of infections by such agent, in
critically ill patientes [10], such evidence including decreased
infection rates by the microorganism after treatment of nare-
colonized patients [5,9,11]. Mupirocin topic antibiotic of
excellent antibacterial activity against S. aureus, including
MRSA, is currently deemed the drug of choice for
decolonization [12,13], although its long-term use may give
rise to resistant strains. [14]
Materials and Methods
Setting
Hospital São Paulo (São Paulo, Brazil) – São Paulo Federal
University tertiary-care referral university hospital, with 600
beds and 10 intensive-care units. The unit studied is a general
ICU for adults with 16 beds, 10 of which are distributed
throughout a large ward and six throughout smaller individual
wards.
Patients and Methods
Prospective cohort study conducted on all patients
hospitalized consecutively in the unit, who met the hospital
infections epidemiologic surveillance enrollment criteria
according to the National Nosocomial Infections Surveillance
System (NNISS) [15], from June 1, 1996 to June 30, 1998 and
divided, by periods, into control, intervention and post-
intervention groups.
Control Group
June 1, 1996 through October 31, 1996, period wrich the
unit routine was kept, in compliance with the NNISS hospital
infections surveillance, intensive-care unit component.
Intervention Group
November 1, 1996 through October 31, 1997. Besides the
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NNISS hospital infection surveillance, culture from the anterior
nares of all of the unit inpatients was collected, within the first
48 hours of hospitalization and, after that, on a weekly basis
until discharge or death. The healthcare workers (HCWs) also
had culture from their anterior nares collected as of March
1997, which was repeated every two months.
Anterior nare samples were collected by using an auginate
swab (Bionet®) and taken to the Clinical Microbiology Special
Laboratory in 0.7% semi-solid nutrient agar (Difco®). Each
sample was cultured on a blood agar plate supplemented with
5% defibernized sheep blood and inoculated in triptona soy
broth vials (TSB-Oxoid®), followed by a 24-hour 35º-37ºC
aerobic inoculation. Plate-isolated colonies suspected of
staphylococci contamination (morphological characteristics,
presence of hemolysis, and, pigment production analyzed)
were presumptively identified by Gram staining, followed by
another 24 hour isolation in blood agar, before they were
submitted to the Staph-test for serologic evidence (Difco®).
The samples were assessed for oxacillin and mupirocin
susceptibility, by means of Disk Diffusion susceptibility tests
and agar screening (Gold standard), in compliance with the
procedures set out by the NCCLS (1997a, 1997b) [16,17]. For
every sample, a bacterial growth suspension was prepared in
5 mL of Mueller-Hinton broth (MHB-Oxoid®) and turbidity
was adjusted to 0.5 on the McFarland scale by means of an
Abbott-A-Just (Abbott®) nephelometer. Following
homogenization of the suspension, the suspension was
cultured on a plate containing Mueller-Hinton Agar (MHA-
Oxoid®) and later antibiotic disks were added: oxacillin (1 µg -
Sensifar®) and mupirocin (5 µg-Sensifar®). The plates were
incubated at 35ºC for 18-24 hours, and their halo was then
measured. Oxacillin-resistance was considered a halo diameter
growth inhibition equal to or smaller than 10 mM, or one smaller
than or equal to 14 mM for mupirocin. The isolate was swab-
plated on Mueller-Hinton Agar supplemented with 4% NaCl
and oxacillin (6 µg/mL). The plates were incubated at 35ºC for
24 hours for later reading. For the control of both tests, strains
of Staphylococcus aureus ATCC 25923-oxacillin-sensitive and
Staphylococcus aureus ATCC 33591- oxacillin-resistant, were
used.
Cultures from other sites, such as tracheal secretions, skin
and urine, were collected according to service routine, which
was not changed during the study. From April 1997 on, along
with the nasal swab collection, HCWs had an educational
measures program implemented. Such guidance was provided
in the unit itself through explanatory classes to nurse aids
and nurse technicians, hygiene and administrative
professionals, within their working hours, focusing on the
epidemiology of the microorganism particularly on its
transmission mechanisms and control measures.  During the
classes, the importance of handwash was emphasized, as well
as the need for each HCW to take on responsibility for the
control of infections. A lecture was given to physicians, nurses
and respiratory therapists, emphasizing the need to implement
control measures to prevent MRSA spread, and showing both
the unit infection rates and the endemic prevalence of the
microorganism.
The use of antiseptic soap (chlorhexidine) for hadwash as
a routine was maintained throughout the study. MRSA-
infected or -colonized patients were not isolated in private
bedrooms on account of the unit lay-out.  Such patients were
identified in their records and/or in a visible place on their
beds (Figure 1), for reinforcement of hygiene measures and
barrier precautions, such as handwash, use of procedure
gloves, overall, surgical masks and the utilization of individual
equipment (stethoscope and sphygmomanometer) or,
otherwise, to have such equipment cleaned with 70% alcohol.
A newssletter with explanations on how to prevent and control
MRSA infections was handed out to all professionals working
in the unit (Figure 2).
All anterior nare colonized patients and professionals were
submitted to a decolonization treatment with topical mupirocin
(nasal Bactroban, SmithKline Beecham) – half a tube in each
nare twice a day for 5 days,  as of May 1997.
Post-Intervention Group
November 1, 1997 through June 30, 1998. The
microorganisms were kept under daily surveillance, isolated
Figure 1. Identification card for MRSA patients.
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by the microbiology laboratory from all organic materials
produced by ICU inpatients so as to diagnose MRSA
infection, and to apply the NNISS methodology in the
epidemiologic analysis of hospital infections. For three months
within this period (January, February and March), we also
assessed the inpatients for the prevalence of MRSA nasal
carriers on a weekly basis, and only once the HCW. The
isolated strains were tested for mupirocin susceptibility.
Definitions
         A MRSA nasal carrier was defined as the patient or
Multiresistant
Staphylococcus aureus
Do you know who that is?
When oxacillin resistant the Staphylococcus aureus
(MRSA) is also resistant to the other β-lactams
(penicillin and by-products, cephalosporin, imipenem
etc.). It is one of the most important carriers of hospital
infections.
Some of its characteristics
1) High prevalence in our ICU (70% of the isolated
S. aureus);
2) Rapid spreading within an institution or between
hospitals;
 3) Causes infection in any environment;
4) High mortality rates.
Main Carriers – patients and healthcare professionals
colonized or infected.
Transmission – direct contact, through hands of the
healthcare workers. The bacteria can remain on the
hands of the workers for minutes, hours or even longer.
How to control?
· Wash your hands with antiseptics or soap and
water before and after handling each patient;
· early identification of the colonized or infected
patient;
· respect the isolation measures of contact
established by CCIH;
· proceed to decolonization of professionals and
patients when suggested by CCIH.
“Your participation is fundamental for control of
hospital Infection”
Join us. CCIH
Figure 2. Bulletin with MRSA information. professional who had at least one positive anterior nare
culture for the microorganism.
Infections were defined according to the criteria
established by the Centers for Disease Control and Prevention
(CDC) [18].
Statistical Analysis
For the analysis of the results, Student’s “t” tests were
used for the average length of stay, and chi-square tests for
non-parametrical data, comparing the control and post-
intervention periods.
Results
A total of 8,883 patients/day (pts/day) were assessed
according to the NNISS methodology – of those, 1,660
(monthly  mean = 332 + 14.08 pts/day) in the control group,
4,072 (monthly  mean = 339 + 51.45 pts/day) in the intervention
group and 3,151 (monthly  mean = 393 + 35.08 pts/day) in the
post-intervention group.
The ratios of invasive device use (NNISS) per patient were
the same for all three periods: control 2.20, at the intervention
2.26, and post-intervention  2.16 (p=0.61).
The incidence coefficients of per site ICU hospital
infections (monthly median per 1,000 pts/day) in the control,
intervention and post-intervention periods were respectively:
global infection rate: 45.7, 56.5, 46.9 (p=0.85); bloodstream
infection: 19.2, 20.7, 6.5 per 1,000 cvc/day (p<0.001);
pneumonia: 25.5, 28.6, 14.2 per 1,000 ventilator/day (p=0.006)
and urinary tract infection: 10.6, 17.9, 14.0 per 1,000 urinary
catheter/day (p=0.36).
The methicillin-suseptible Staphylococcus aureus
hospital infections  remained virtually constant as we
compared the control period, 3.01 infections per 1,000 pts/
day, with the post-intervention period, 0.9 infections per 1,000
pts/day (p=0.09). However, increased Gram-negative bacilli
(P. aeruginosa, A.baumannii, K. pneumoniae and
Enterobacter cloacae) hospital  infections: 21.1 infections/
1,000 pts/day (control) and 33.0 infections/1,000 pts/day (post-
intervention) (p=0.02).
The MRSA global rate of infection was 10.2, 5.1 and 2.5/
1,000 pts/day (p<0.001) and MRSA bloodstream infections
were 3.6, 0.9 and 1.8/1,000 cvc/day (p=0.281) (Figure 3).
MRSA nasal colonization in ICU patients was 30.9 in the
intervention period and 22.0 in the post-intervention period
(p=0.06) (Table 1).
Among the MRSA nasal carriers in the intervention group,
58.0% were positive at admittance to the ICU, 22.0% became
positive in the first week and 20.0% from the second week on.
In the post-intervention group, those rates were 46.1%, 26.9%
and 26.9%, respectively.
In regard to the nasal carrier vs. infection ratio in the
intervention group, we found 76.2% of patients who developed
MRSA hospital infection to be nasal carriers, whereas 23.8%
of the MRSA-infected patients carried no such microorganism
in their nares. In the post-intervention group, 100% of the
MRSA Control in ICU
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Figure 3.  MRSA global and bloodstream infection rate in the
control, intervention and post-intervention groups – ICU
patients – São Paulo Hospital – UNIFESP – JUN/96 to JUN/
98.
Table 1.  ICU patients evaluated with nare cultures for
meticillin-resistant (MRSA) and methicillin-susceptible
(MSSA) Staphylococcus aureus in the intervention and post-
intervention periods – São Paulo Hospital – UNIFESP – NOV/
96 to JUN/98
Patients No MRSA MSSA Non-
carriers carriers carriers
No  (%) No (%) No (%)
Intervention 333 103 (30.9) 48 (14.4) 182 (54.7)
Post- intervention 118 26 (22.0) 25 (21.2) 67 (56.8)
P=0.20 (comparison among MRSA carriers in the intervention and
post-intervention periods).
MRSA-infected patients were nare-colonized  (Table 2).
MRSA-nare colonized patients were at a 7.1 (CI – 95% = 2.7–
18.9) higher risk of developing infection caused by the
microorganism than those not colonized in their nares.
The average time between colonization and development
of infection was 8.5 (1 to 31) days and the median was 5.5
days.
Analysis of HCW for MRSA nasal colonization showed a
12.1% prevalence in the intervention period (Table 3), with
predominance of nursing professionals (nurses and nurses’
aids) over the others. In the post-intervention period, of the
108 HCWs assessed, 4.6% were MRSA positive (p=0.037).
No physicians, nurses or respiratory therapists were positive
(Table 3).
The efficacy of topical mupirocin treatment to eliminate
nasal carriers in patients was 93.7% (30/32), and 88.2% (15/17)
in HCWs.
The patients’ tested strains showed 1.9% (5/259) mupirocim
resistance in the intervention group and 1.28% (1/78) in the
post-intervention group (p=0.709). In either period no mupirocin
resistance in the isolated samples of HCW were founded.
The patients’ ICU length of stay, in the three periods was
11.3, 15.1 and 12.7 days, respectively (p= 0,76).
The mortality rate (%) in the three periods was respectively,
26.6, 27.2 and 21.0 (p<0.001).
Among the Staphylococcus aureus strains isolated from
several sites in the three periods, respectively 64.5%, 84.6% and
71.1% of oxacillin resistance (p=0.31) was found.
Discussion
Although we are aware that the acquisition of MRSA is an
important event in the hospitalized patient, mainly in ICUs,
little is known about the efficacy of control measures when
MRSA Control in ICU
Table 2. ICU patients who developed MRSA infection in
relation to the previous nasal carrier condition in the
intervention and post-intervention groups – São Paulo
Hospital – UNIFESP – NOV/96 to JUN/98
               MRSA Infection
MRSA nasal
Non-carriers Totalcarriers
No (%) No (%) No (%)
Intervention group 16 (76.19) 5 (23.80) 21 (100)
Post-intervention 2 (100.00) 0 (0.00) 2 (100)
  group
Table 3. Healthcare workers  MRSA nasal colonized in the intervention and post-intervention periods – São Paulo Hospital –
UNIFESP – MAR/97 to JUN/98
               Intervention period     Post-intervention period
Assessed MRSA Assessed MRSA
professionals nasal carriers professionals nasal carriers
N (%) N (%)
Nurse aides and Nurse technicians 66 11 (16.66) 70 5 (7.14)
Physicians 37 1 (2.70) 14 0 (0.00)
Registered Nurses 36 6 (16.66) 18 0 (0.00)
Respiratory Therapists 3 0 (0.00) 2 0 (0.00)
Administration/ Hygiene 6 0 (0.0) 4 0 (0.0)
Total 148 18 (12.16) 108 5 (4.62)
www.bjid.com.br
BJID 2007; 11 (February) 6 1
the microorganism is endemic, as it occurs in most of the large
Brazilian university hospitals.
The ICU studied is a service which attends to both clinical
and surgical patients either from the emergency room or from
other areas of the hospital. It poses high prevalence of MRSA
and it is likely to spread the microorganism to other areas
through the exchange of patients.
The adoption of MRSA control measures is highly
discussed in the literature and their efficacy, and even the
worthness of implementing them, is controversial [4,6,9]. The
different needs to control the microorganism experienced by
the institutions, associated with recent changes in its
epidemiology, such as increased community cases [1] and the
importance of environmental surface contamination, render
the problem even more complex [19].
Control strategies should be developed by each institution
based on factors such as: whether it is an endemic situation,
an outbreak, the population of patients, the type of unit and
the resources available for infection control. In low prevalence
or non-endemic MRSA institutions, strict application of
standard measures can effectively curb transmission [7]. The
control program shown in the study, which included early
identification of infected and colonized patients, guidance
measures, modified contact isolation and treatment of nasal
carriers with intranasal mupirocin ointment, was effective in
reducing the incidence of bloodstream infections, pneumonia
and hospital infections caused by MRSA in our ICU patients.
The intervention made no impact on the length of stay in the
unit, but it reduced the overall mortality rate significantly.
Some studies show the efficacy of such measures in an endemic
situation [4,5,7,8], and outbreaks that were controlled with
the implementation of such measures are also reported in the
literature.
The isolation of MRSA-colonized or infected patients is a
recommended measure, but difficult to be applied in our reality
due to structural problems in the hospitals. Alternative
isolation measures proved to be equally effective when
applied to specific units [20,21].
MRSA nasal colonization in patients admitted to the ICU
was high in the intervention period showing slight decline in
the post-intervention period. Most of such patients were
already colonized at admittance to the unit. When we evaluated
the MRSA nare-positive patients alone, in the intervention
period, 31.4% of such patients were found to have been
inpatients for less than 48 hours, which corrobrates the
relevance of assessing the MRSA carrier at admittance to a
unit where control measures are being implemented,
considering the growing prevalence that microorganism in
the community [22]. Furthermore, in the intervention and post-
intervention groups respectively, 22.0% and 26.9% of patients
were found to have become positive in the first week of
admittance to the ICU, which shows the high risk of nasal
MRSA acquisition in an endemic situation. MRSA nasal
carriers rates rang from 5.6% to 12.9% in ICU patients [5,10,23],
such rates being lower than the ones found in our study. As
yet, little is known about the MRSA nasal carrier epidemiology
in ICU patients or its subsequent clinical consequences, since
few in-depth investigations have been made.
Murder et al. [24] evaluated the development of
staphylococcal infection in methicillin-resistant (MRSA) and
methicillin-susceptible (MSSA) S. aureus nasal carriers and
found that 25% of patients who developed infection were
MRSA carriers, whereas among MSSA carriers or non-carriers,
as few as 4% and 4.5% respectively developed infections
(73% of all MRSA infections occurred in nasal carriers of the
microorganism). They also concluded that the management
of carriers may be used as a control measure.
We found an association between the MRSA nasal carrier
and further development of infection caused by the
microorganism in several sites. Of the patients who developed
proven MRSA infection, 76.1% carried the microorganism in
their nares, accounting for a 7 times higher risk for that
colonized patients. MRSA colonization and the risk of infection
in critically ill patients has been described [24].
Pujol et al., in an ICU study, concluded that S. aureus nasal
carriers are at a high risk for the development of bacteremia by
the microorganism and suggest that treatment of those
patients may be effective in controlling the agent [10].
Elimination of nasal carriage with topical mupirocin proved
to be effective in our study, in agreement with other reports
[5,8,25]. Mupirocin resistance was not significant in our study,
probably due to its brief use.
The high prevalence of MRSA nare colonized HCW is an
event not found by other authors in an endemic or epidemic
situation, not even in risk units [5,25,26]. Of course in critical
units, direct and long term contact between professionals and
patients predisposes to increased colonization when high
endemic rates are found. In the post-intervention period a nasal
carriage decrease of approximately 60% was noticed among the
professionals (p=0.037) probably due to the decreased
incidence of MRSA infection which could be a source of
environmental contamination since those professionals had
been exposed to the patients while attending them.
MRSA infections declined following implementation of
the procedures. However, reduction of nasal colonization
among patients, hasn’t been observed even when only the
ones who had become positive in the ICU were assessed.
As the number of MRSA nasal carriers decreased among
the professionals, can we consider that they were not
important as a reservoir and also in the transmission of the
microorganism?
In order to compare the length of stay and the mortality
rate among the patients hospitalized in the control and post-
intervention periods, we used the device use ratio as an
indicator of the patients’ nosological conditions.
Since those periods were equivalent, it may be said that
no important changes occurred in the inpatients severity
condition during our study.
Despite no changes to the length of hospital stay, a
decrease in the overall mortality rate in the period subsequent
MRSA Control in ICU
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to the procedures implementation was found, probably as a
result of reduced pneumonia, bloodstream and MRSA
infections, that are known to cause high mortality.
In conclusion, control measures should be introduced in
risk areas of MRSA endemic hospitals, even if the procedures
cannot be carried out throughout the institution.  However,
further studies should be conducted for the relevance of each
procedure to be evaluated distinctly.
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